No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
www.hikal.comNo one on the platform currently holds HIKAL.NS.
No tracked institution reports a position in HIKAL.NS as of their last filing.
No one on the platform has traded HIKAL.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -7.9% | 0.1% | ||||
| Profit Margin % | -2.8% | 3.6% | 5.1% | |||
| Free Cash Flow Margin % | 5.2% | 2.7% | 3.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $18.8B | +8.0% | $3.00 | $3.00–$3.00 | — | 1 |
| 2028 | $21.4B | +13.8% | $9.00 | $9.00–$9.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| HIKAL.NSHikal Limited | $212.22 | -5.66% | $26.2B | — |
| GUFICBIO.BOGufic Biosciences Limited | $425.00 | -1.16% | $42.6B | — |
| GUFICBIO.NSGufic Biosciences Limited | $425.10 | +0.00% | $42.6B | — |
| IOLCP.BOIOL Chemicals and Pharmaceuticals Limited | $179.45 | -7.26% | $52.7B | — |
| IOLCP.NSIOL Chemicals and Pharmaceuticals Limited | $179.52 | -7.61% | $52.7B | — |
| MOREPENLAB.BOMorepen Laboratories Limited | $106.25 | -8.37% | $58.3B | — |
| MOREPENLAB.NSMorepen Laboratories Limited | $106.22 | -8.26% | $58.2B | — |
Source: Financial Modeling Prep · peers by sector/industry